SRPT: 萨雷普塔治疗

SRPT新闻

• 12:34 Sarepta Says SRP-1003 Cut Disease-Causing RNA In Cell Nucleus By Up To ~80% In Preclinical Myotonic Dystrophy Model
• 14:10 RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17
• 12:17 Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’
• 12:17 Jim Cramer：这只科技股“非常不错”，艾利丹尼森是“赢家”
• 11:54 HC Wainwright & Co. 重申对 Sarepta Therapeutics 的“卖出”评级，维持 5 美元目标价
• 11:54 HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target
• 18:11 JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20
• 12:38 Sarepta Therapeutics Presents New Data At 31st Annual Congress Of WMS That Provide Evidence Of Clinically Meaningful Functional Benefit Of ELEVIDYS In Older Ambulatory Patients With Duchenne Muscular Dystrophy
• 12:38 Sarepta Therapeutics在第31届WMS年会上公布新数据，提供了ELEVIDYS在较年长、仍可行走的杜氏肌营养不良症患者中具有临床意义功能获益的证据
• 18:44 uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish (QURE)
• 10:14 Needham Reiterates Underperform on Sarepta Therapeuticsto Underperform
• 20:21 REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids
• 20:21 REGENXBIO表示所有有关专利诉讼将被终止并带有成见；同意不起诉Sarepta或其关联公司，以及现有的Elevidys或AAVrh74基础的胶囊。
• 18:21 Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
• 15:16 Stock Market Falls On Soaring Oil Prices, Yields, But Finishes Strong; CPI Inflation, Apple, Oracle, Meta In Focus: Weekly Review
• 11:45 Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class (NASDAQ:DYN)
• 20:32 Stocks Settle Lower on Middle East Jitters
• 12:01 Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Baidu
• 15:30 Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?
• 16:53 KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
• 16:51 Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
• 18:05 Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated
• 00:35 Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates
• 00:30 Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics